XML 48 R26.htm IDEA: XBRL DOCUMENT

Components of Expenses

12 Months Ended

Dec. 31, 2023

Analysis of income and expense [abstract]


	2023		2022		2021
Research and development expenses
Clinical trial expenses	$	3,675	$	4,970	$	3,205
Manufacturing & related process development expenses	5,789		2,148		1,547
Intellectual property expenses	397		544		618
Translational science expenses	—		264		673
Personnel-related expenses	6,324		6,023		4,754
Share-based compensation expense	1,305		1,371		2,087
Other expenses	219		112		36
	$	17,709	$	15,432	$	12,920


	2023		2022		2021
General and administrative expenses
Public company-related expenses	$	11,278	$	6,790	$	8,161
Office expenses	3,789		3,303		2,963
Share-based compensation expense	612		1,007		1,739
Depreciation - property and equipment	81		93		130
Depreciation - right-of-use assets	322		299		322
	$	16,082	$	11,492	$	13,315

For the year ended December 31, 2023, our research and development personnel-related expenses included employee compensation and benefits of $6,324 (2022 - $5,983; 2021 - $4,645).

For the year ended December 31, 2023, our general and administrative office expenses included employee compensation and benefits of $3,332 (2022 - $2,870; 2021 - $2,542).